We've just updated our listing of industry-sponsored pivotal, ph3 and 2/3 cell therapy trials again. See the posting here.
According to our data, approximately 50% of these trials are expected to have reached their estimated primary completion date or some other meaningful trial completion point within the next 12 months.
No comments:
Post a Comment